Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 1, 2012, Pages 215-220

  Quarto, Natalina ^a,b   Leonard, Brian ^a,c   Li, Shuli ^a   Marchand, Melanie ^a   Anderson, Erica ^a   Behr, Barry ^a   Francke, Uta ^a   Reijo Pera, Renee ^a   Chiao, Eric ^a,c   Longaker, Michael T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOCALCIN; SMAD2 PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BLASTOCYST; BONE DEVELOPMENT; CELL CULTURE; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; EXON; FERTILIZATION IN VITRO; FIBROBLAST; GENE MUTATION; HEREDITY; HUMAN; HUMAN CELL; MALE; MARFAN SYNDROME; MOLECULAR DIAGNOSIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; ONCOGENE C MYC; OSTEOBLAST; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION; UPREGULATION;

BASE SEQUENCE; BONE AND BONES; CELL DIFFERENTIATION; CHONDROGENESIS; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MARFAN SYNDROME; MICROFILAMENT PROTEINS; MOLECULAR SEQUENCE DATA; OSTEOGENESIS; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84862929910     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1113442109     Document Type: Article

References (59)

1. Dietz HC, et al. (1991) Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352:337-339. (Pubitemid 21912353)
2. Pereira L, et al. (1997) Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 17:218-222.
3. Dietz HC, Loeys B, Carta L, Ramirez F (2005) Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet 139C:4-9. (Pubitemid 41739241)
4. Robinson PN, et al. (2006) The molecular genetics of Marfan syndrome and related disorders. J Med Genet 43:769-787. (Pubitemid 44654735)
5. McKusick VA (1991) The defect in Marfan syndrome. Nature 352:279-281.
6. Pyeritz RE, McKusick VA (1979) The Marfan syndrome: Diagnosis and management. N Engl J Med 300:772-777. (Pubitemid 9172315)
7. Pyeritz RE (2000) The Marfan syndrome. Annu Rev Med 51:481-510.
8. McKUSICK VA (1955) The cardiovascular aspects of Marfan's syndrome: A heritable disorder of connective tissue. Circulation 11:321-342.
9. Gelb BD (2006) Marfan's syndrome and related disorders - More tightly connected than we thought. N Engl J Med 355:841-844.
10. Hayward C, Brock DJ (1997) Fibrillin-1 mutations in Marfan syndrome and other type- 1 fibrillinopathies. Hum Mutat 10:415-423. (Pubitemid 27523052)
11. Pereira L, et al. (1993) Genomic organization of the sequence coding for fibrillin, the defective gene product in Marfan syndrome. Hum Mol Genet 2:1762.
12. Ramirez F, Pereira L (1999) The fibrillins. Int J Biochem Cell Biol 31:255-259. (Pubitemid 29094775)
13. Dietz HC, Pyeritz RE (1995) Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 4(Spec No):1799-1809.
14. Adès LC, et al. (2006) FBN1, TGFBR1, and the Marfan- craniosynostosis/mental retardation disorders revisited. Am J Med Genet A 140:1047-1058.
15. Faivre L, et al. (2010) De novo 15q21.1q21.2 deletion identified through FBN1 MLPA and refined by 244K array-CGH in a female teenager with incomplete Marfan syndrome. Eur J Med Genet 53:208-212.
16. Hutchinson S, et al. (2003) Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: A potential modifier of phenotype? Hum Mol Genet 12:2269-2276. (Pubitemid 37160871)
17. Blyth M, Foulds N, Turner C, Bunyan D (2008) Severe Marfan syndrome due to FBN1 exon deletions. Am J Med Genet A 146A:1320-1324. (Pubitemid 351631331)
18. Dietz HC, et al. (1993) Four novel FBN1 mutations: Significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics 17:468-475. (Pubitemid 23231307)
19. Liu W, Schrijver I, Brenn T, Furthmayr H, Francke U (2001) Multi-exon deletions of the FBN1 gene in Marfan syndrome. BMC Med Genet 2:11.
20. Mátyás G, et al. (2007) Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome. Hum Genet 122:23-32. (Pubitemid 47040570)
21. Zhu L, et al. (2006) Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 38:343-349.
22. Guo DC, et al. (2007) Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 39:1488-1493.
23. Carta L, et al. (2006) Fibrillins 1 and 2 perform partially overlapping functions during aortic development. J Biol Chem 281:8016-8023. (Pubitemid 43847419)
24. Judge DP, et al. (2004) Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 114:172-181. (Pubitemid 39071622)
25. Eldadah ZA, Brenn T, Furthmayr H, Dietz HC (1995) Expression of a mutant human fibrillin allele upon a normal human or murine genetic background recapitulates a Marfan cellular phenotype. J Clin Invest 95:874-880.
26. Charbonneau NL, et al. (2010) In vivo studies of mutant fibrillin-1 microfibrils. J Biol Chem 285:24943-24955.
27. Neptune ER, et al. (2003) Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33:407-411. (Pubitemid 36278859)
28. Liu W, et al. (1996) Mutant fibrillin-1 monomers lacking EGF-like domains disrupt microfibril assembly and cause severe marfan syndrome. Hum Mol Genet 5:1581-1587. (Pubitemid 26328874)
29. Schrijver I, et al. (2002) Premature termination mutations in FBN1: Distinct effects on differential allelic expression and on protein and clinical phenotypes. Am J Hum Genet 71:223-237. (Pubitemid 34800240)
30. Byrne JA, Nguyen HN, Reijo Pera RA (2009) Enhanced generation of induced pluripotent stem cells from a subpopulation of human fibroblasts. PLoS ONE 4:e7118.
31. Tuli R, et al. (2003) Characterization of multipotential mesenchymal progenitor cells derived from human trabecular bone. Stem Cells 21:681-693. (Pubitemid 37329161)
32. Liu GH, et al. (2011) Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472:221-225.
33. Liu H, et al. (2009) A subpopulation of mesenchymal stromal cells with high osteogenic potential. J Cell Mol Med 13(8B):2436-2447.
34. Bühring HJ, et al. (2007) Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 1106:262-271.
35. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ (1991) Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem 266:23048-23052. (Pubitemid 21908758)
36. Laping NJ, et al. (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58-64. (Pubitemid 34680516)
37. Ignotz RA, Massagué J (1986) Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261:4337-4345. (Pubitemid 17198877)
38. Penttinen RP, Kobayashi S, Bornstein P (1988) Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci USA 85:1105-1108. (Pubitemid 18073964)
39. Inman GJ, et al. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65-74. (Pubitemid 34680517)
40. Mello MA, Tuan RS (2006) Effects of TGF-beta1 and triiodothyronine on cartilage maturation: in vitro analysis using long-term high-density micromass cultures of chick embryonic limb mesenchymal cells. J Orthop Res 24:2095-2105. (Pubitemid 44717972)
41. Kawaguchi J, Mee PJ, Smith AG (2005) Osteogenic and chondrogenic differentiation of embryonic stem cells in response to specific growth factors. Bone 36:758-769. (Pubitemid 40616010)
42. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU (1998) In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res 238:265-272. (Pubitemid 28366150)
43. Hanna JH, Saha K, Jaenisch R (2010) Pluripotency and cellular reprogramming: Facts, hypotheses, unresolved issues. Cell 143:508-525.
44. Panopoulos AD, Ruiz S, Izpisua Belmonte JC (2011) iPSCs: Induced back to controversy. Cell Stem Cell 8:347-348.
45. Faivre L, et al. (2007) Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: An international study. Am J Hum Genet 81:454-466. (Pubitemid 47330205)
46. Mayshar Y, et al. (2010) Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7:521-531.
47. Laurent LC, et al. (2011) Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8:106-118.
48. Lister R, et al. (2011) Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471:68-73.
49. Gore A, et al. (2011) Somatic coding mutations in human induced pluripotent stem cells. Nature 471:63-67.
50. Hussein SM, et al. (2011) Copy number variation and selection during reprogramming to pluripotency. Nature 471:58-62.
51. Habashi JP, et al. (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:117-121.
52. Kohlmeier L, Gasner C, Marcus R (1993) Bone mineral status of women with Marfan syndrome. Am J Med 95:568-572. (Pubitemid 24002374)
53. Kohlmeier L, Gasner C, Bachrach LK, Marcus R (1995) The bone mineral status of patients with Marfan syndrome. J Bone Miner Res 10:1550-1555.
54. Moura B, et al.; Multidisciplinary Marfan Syndrome Clinic Group (2006) Bone mineral density in Marfan syndrome. A large case-control study. Joint Bone Spine 73:733-735. (Pubitemid 44918419)
55. DeLise AM, Fischer L, Tuan RS (2000) Cellular interactions and signaling in cartilage development. Osteoarthritis Cartilage 8:309-334.
56. Tuli R, et al. (2003) Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk. J Biol Chem 278:41227-41236. (Pubitemid 37280950)
57. Giampietro PF, Raggio C, Davis JG (2002) Marfan syndrome: Orthopedic and genetic review. Curr Opin Pediatr 14:35-41. (Pubitemid 34169567)
58. Quarto N, et al. (2010) Origin matters: differences in embryonic tissue origin and Wnt signaling determine the osteogenic potential and healing capacity of frontal and parietal calvarial bones. J Bone Miner Res 25:1680-1694.
59. Quarto NWD, Wan DC, Longaker MT (2008) Molecular mechanisms of FGF-2 inhibitory activity in the osteogenic context of mouse adipose-derived stem cells (mASCs). Bone 42:1040-1052.